methsuximide 300 MG Oral Capsule [Celontin]
methsuximide
RxCUI: 207088
What the CMS Formulary Data Shows for methsuximide 300 MG Oral Capsule [Celontin]
Per the CMS 2026 Part D formulary file, methsuximide 300 MG Oral Capsule [Celontin] (RxNorm concept RXCUI 207088, generic name methsuximide) appears on 10 distinct formulary files spanning 163 Medicare Part D plan offerings - 3.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.2.
Real-world access to methsuximide 300 MG Oral Capsule [Celontin] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 217 Part D beneficiaries filled methsuximide 300 MG Oral Capsule [Celontin] in 2023, with total plan-and-beneficiary spending of $695,875 and an average per-beneficiary annual cost of $3,206.80. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry methsuximide 300 MG Oral Capsule [Celontin] today.
Coverage Details
- Formularies covering
- 10
- Plans covering
- 163
- Coverage rate
- 3.2%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 217
- Total spending
- $695,875
- Avg per beneficiary
- $3,206.80
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering methsuximide 300 MG Oral Capsule [Celontin]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is methsuximide 300 MG Oral Capsule [Celontin] covered by Medicare Part D?
Yes, methsuximide 300 MG Oral Capsule [Celontin] is covered by 163 Medicare Part D plans (3.2% of all Part D formularies).
What tier is methsuximide 300 MG Oral Capsule [Celontin] on Medicare Part D plans?
methsuximide 300 MG Oral Capsule [Celontin] averages Tier 3.2 across Part D plans, ranging from Tier 1 to Tier 4.
Does methsuximide 300 MG Oral Capsule [Celontin] require prior authorization?
0% of Part D formularies require prior authorization for methsuximide 300 MG Oral Capsule [Celontin]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on methsuximide 300 MG Oral Capsule [Celontin]?
In 2023, total Medicare Part D spending on methsuximide 300 MG Oral Capsule [Celontin] was $695,875, covering 217 beneficiaries. The average spend per beneficiary was $3,206.80.
Read our methodology - how this data is sourced, computed, and verified.